Antiangiogenic Gene Therapy for Hepatocellular Carcinoma Using Angiostatin Gene

• DOI: 10.1053/jhep.2003.50077
• Publication Date: 2003-03-15T12:29:29Z
• Authors: Hiroki Ishikawa; Kazuhiko Nakao; Kojiro Matsumoto; Tatsuki Ichikawa; Keisuke Hamasaki; Keisuke Nakata; Katsumi Eguchi
• Keywords: Angiostatin

Recent studies have reported that antiangiogenic gene delivery into cancer cells inhibits growth of certain tumors in vivo. Hepatocellular carcinoma (HCC) is a hypervascular cancer, and therapy might be suitable for HCC. In the present study, we investigated effects angiostatin transduction HCC both vitro Angiostatin was cloned pSecTag2B mammalian expression vector to construct pSecTag2B-ANG. or pSecTag2B-ANG were transfected an cell line, PLC/PRF/5, then stable transfectants obtained by Zeocin selection. transfection did not alter vascular endothelial factor (VEGF), potent angiogenic stimulator, pigment epithelium-derived (PEDF), inhibitor, PLC/PRF/5 cells. However, conditioned media (CM) derived from pSecTag2B-ANG-transfected (CM-ANG) suppressed proliferation migration human umbilical vein (HUVEC) 35% 50%, respectively, relative their on nontransfected vivo experiments, (CM-Mock) (CM-N) mixed at various proportions subcutaneously implanted athymic mice. Suppression tumor noted mice with gene-transfected cells, such suppression proportional percentage Analysis density these showed effect correlated vascularity. conclusion, using potentially treatment patients